Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.43 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.43 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21674280 | 0.81 | SIGMAR1 (0.61) | SIGMAR1TAAR1 | |
| SCHEMBL1967415 | 0.78 | KDM4E (0.43) | SIGMAR1CHI3L1CHIT1CHI3L2CHIA | |
| SCHEMBL619732 | 0.75 | SLC6A2 (0.50) | — | |
| SCHEMBL1970890 | 0.74 | CHIT1 (0.47) | SIGMAR1CHI3L1CHIT1CHI3L2CHIA | |
| SCHEMBL8828505 | 0.74 | TAAR1 (0.50) | SIGMAR1TAAR1 | |
| SCHEMBL8255914 | 0.73 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL2406397 | 0.72 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL30101707 | 0.72 | TAAR1 (0.61) | SIGMAR1TAAR1 | |
| SCHEMBL25519810 | 0.72 | TAAR1 (0.61) | SIGMAR1TAAR1 | |
| SCHEMBL1967604 | 0.72 | SIGMAR1 (0.60) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | SIGMAR1 108/4885CHI3L1 2780/4885CHIT1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.